2020 cfDNA testing for EGFR mutations in lung cancer

Scheme description
Circulating free DNA(cfDNA) testing for EGFR variant in plasma for lung cancer . Three samples to be sent out of articifical plasma.
Disorders/Gene target(s)
Lung Cancer EGFR circulating tumour DNA (cfDNA)
Clinical cases
3
Testing/analysis
circulating tumour DNA variant hotspots in EGFR
Sample type
Artificial plasma
Techniques
Any molecular testing methods.
Assessment
Submit a clinical report to include: • Genotyping of results • Interpretation of the result • Clerical accuracy
Eligibility
Any laboratory worldwide
Languages
English ONLY
ISO17043 Accredited EQA
No
EQA timeline
Sample dispatchSeptember 2020
Testing period6 weeks
Assessment resultsFebruary 2021
Final Summary reportMarch 2021
Other information
Collaboration with EMQN CIC.
This EQA is supported by an educational grant from Astra Zeneca. 
Fee
£0.00
GenQA code
2020CFDNAL
« Return to EQA scheme list
Go to top